Filing Flows › 8-K events › Aptevo Therapeutics
Aptevo Therapeutics: entry into a material definitive agreement
Form 8-K filed Oct 23, 2026 · items 1.01, 3.03
What the filing says
On October 23, 2026, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 6 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent (as amended and/or restated from time to time, the “Rights Agreement”).
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 3.03: +0.1% next session across 1,456. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.